The Fund’s largest detractors from performance in the fourth quarter included Jazz Pharmaceuticals, Boyd Gaming, Park Hotels ...

Piper Sandler reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report ...

Jazz lovers will not want to miss the incredible evening of music lined up at Clarksville's oldest professional live theatre in March.

Explore Jazz's (JAZZ) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.

Praxis Precision Medicines said an independent committee had recommended stopping a late-stage trial of an experimental drug for a movement disorder as it was unlikely to meet the main goal, sending ...

Fintel reports that on February 26, 2025, Cantor Fitzgerald downgraded their outlook for Jazz Pharmaceuticals (NasdaqGS:JAZZ) ...

Barclays analyst Balaji Prasad raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $200 from $190 and keeps an Overweight rating ...

New York State Common Retirement Fund lessened its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) ...

Cantor downgraded Jazz Pharmaceuticals (NASDAQ:JAZZ) to neutral from overweight, citing the company's increasing focus on ...

Jazz Pharmaceuticals ended 2024 on a strong note, beating analyst estimates. I continue to see Jazz stock as a valuation ...

Highlights,CIBC Asset Management and UMB Bank have boosted their stakes in Jazz Pharmaceuticals.,The company continues to ...

We maintain our fair value estimate of $187 per share. Xywav (for excessive daytime sleepiness), Epidiolex (for childhood epilepsy), and Rylaze (for leukemia) have continued to be Jazz’s primary ...